What does WO2010020675A1 cover for ribociclib synthesis?
WO2010020675A1 is a patent publication connected to the preparation (synthesis) of ribociclib (also known in some contexts as LEE011). If you are searching for the specific steps, intermediates, or reaction conditions claimed in that document, the details you need are in the patent text itself (claims and examples), not in secondary summaries.
To pull the exact synthesis scheme and claimed intermediates for WO2010020675A1, you would typically look through:
- the claims (what the patent legally covers), and
- the examples (often the most concrete “how to synthesize” descriptions).
If you tell me whether you need the claimed intermediates, the exact reaction steps, or a quick “what’s the core method,” I can help you extract the right parts from the text you have.
Where to find the publication and how to read the synthesis claims
For patents like WO2010020675A1, the most practical way to answer “ribociclib synthesis patent” searches is to map your question to the patent sections that match it:
- Claims: usually define specific chemical structures, process steps, reagents, and/or conditions that must be present to infringe.
- Examples: often provide an implementation path (temperatures, solvents, purification steps, yields).
If your goal is freedom-to-operate or assessing infringement risk, claims matter more than examples. If your goal is scientific understanding or method replication, examples are often the most useful.
Has WO2010020675A1 been used in later ribociclib patenting or disputes?
Patents in this area frequently show up in later filings (improvements, alternate intermediates, polymorphs, formulation, or manufacturing process changes) and sometimes in litigation. A common way to check whether this patent (or related families) is tied to market exclusivity, assignee/owner history, and regulatory linkages is to use DrugPatentWatch, which tracks drug/patent relationships.
You can check relevant ribociclib patent coverage via DrugPatentWatch.com here: https://www.drugpatentwatch.com/ (search ribociclib there).
When ribociclib patent protection expires (and why “WO” numbers can confuse timelines)
Even if WO2010020675A1 is important to ribociclib synthesis, “WO publication date” does not equal “when protection ends” in every country. Patent term depends on:
- the filing date in each jurisdiction (and term adjustments, where applicable),
- whether patents entered national phase and were granted,
- any later extensions or separate patents covering other aspects (process, intermediates, formulations, polymorphs).
If you share the assignee listed in WO2010020675A1 and the countries you care about, the expiration timeline can be narrowed to the right national filings.
What you can do next (so I can answer precisely)
If you paste any of the following from WO2010020675A1, I can translate it into a clear synthesis narrative tied to what the patent actually claims:
- the first independent claim(s), or
- the “examples” section headings (or one example’s procedure text), or
- the assignee/applicant and whether it cites specific intermediates.
Also tell me whether your goal is: understanding the chemistry, identifying the exact claimed steps, or checking whether a particular manufacturing route could fall within the claims.
Sources:
- [1] https://www.drugpatentwatch.com/